Literature DB >> 2306738

Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).

H Masuda1, T Tanaka, H Matsuda, I Kusaba.   

Abstract

A human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II) (DDP) (2780CP) was compared with its DDP-sensitive parental cell line (A2780) to determine whether differences in the removal rate of DNA-bound platinum were related to resistance. Both cell lines were treated in vitro with various doses of DDP for 2 h and subsequently incubated in arginine-deficient Eagle's minimum essential medium with 2.5% dialyzed fetal bovine serum in the presence or absence of aphidicolin. After 0, 12, and 24 h, DNA was isolated from the cells and DNA-bound platinum was determined by flameless atomic absorption spectrophotometry. Binding of platinum to DNA of either cell line was a linear function of concentration ranging from 20 to 80 microM DDP. Platinum binding was almost equal at each dose in both cell lines. 2780CP cells that were 3-fold resistant to DDP lost 30.5 to 40.1% of their total DNA-bound platinum, compared with a 1.3 to 16.1% loss for A2780 cells, 12 to 24 h after a 2-h exposure to 40 microM DDP, respectively. Aphidicolin (3.0 micrograms/ml) increased the cytotoxicity in 2780CP cells by about 2-fold and caused a significant delay in the time required for platinum removal in the resistant cells (14.6 and 18.9% at 12 and 24 h). These studies indicate that the mechanism of DDP resistance in the 2780CP cell line is related to an increased ability to remove platinum-DNA adducts, and not to a difference in initial DDP binding to DNA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306738

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

Authors:  R J Parker; A Eastman; F Bostick-Bruton; E Reed
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 2.  Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.

Authors:  D J Stewart; G P Raaphorst; J Yau; A R Beaubien
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer.

Authors:  K Son; L Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

4.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.

Authors:  W Zhen; C J Link; P M O'Connor; E Reed; R Parker; S B Howell; V A Bohr
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

5.  Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells.

Authors:  L Beketic-Oreskovic; M Osmak
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Lack of cross-resistance to a new cytotoxic arylchloroethyl urea in various drug-resistant tumor cells.

Authors:  R C Gaudreault; M A Alaui-Jamali; G Batist; P Béchard; J Lacroix; P Poyet
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.

Authors:  Qi-En Wang; Keisha Milum; Chunhua Han; Yi-Wen Huang; Gulzar Wani; Jürgen Thomale; Altaf A Wani
Journal:  Mol Cancer       Date:  2011-03-08       Impact factor: 27.401

8.  In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.

Authors:  K J Mellish; L R Kelland; K R Harrap
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

9.  Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.

Authors:  C William Helm; J Christopher States
Journal:  J Ovarian Res       Date:  2009-01-14       Impact factor: 4.234

Review 10.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.